110402-20-5

Basic information

• Product Name: 3-Pyridinethiol,2-amino-(9CI)
• Synonyms: 3-Pyridinethiol,2-amino-(9CI);2-Amino-3-pyridinethiol;2-Amino-3-mercaptopyridine;3-Pyridinethiol, 2-amino;2-aminopyridine-3-thiol;2-aMinopyridin-3-thiol;2-Amino-3-pyridinethio
• CAS NO: 110402-20-5
• Molecular Formula: C₅H₆N₂S
• Molecular Weight: 126.182
• EINECS: 1806241-263-5
• Product Categories: PYRIDINE
• Mol File: 110402-20-5.mol

Chemical Properties

• Melting Point: 158-162 °C
• Boiling Point: 258.9 °C at 760 mmHg
• Flash Point: 110.4 °C
• Appearance: /
• Density: 1.293 g/cm³
• Vapor Pressure: 0.0133mmHg at 25°C
• Refractive Index: 1.677
• PKA: 3.26±0.48(Predicted)
• CAS DataBase Reference: 3-Pyridinethiol,2-amino-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridinethiol,2-amino-(9CI)(110402-20-5)
• EPA Substance Registry System: 3-Pyridinethiol,2-amino-(9CI)(110402-20-5)

Safety Data

• Hazardous Substances Data: 110402-20-5(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
3-Pyridinethiol,2-amino-(9CI) is used as a building block in organic synthesis for the development of various chemical compounds. Its unique structure, containing both an amino and a thiol group, allows for versatile reactions and the creation of a wide range of products.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 3-Pyridinethiol,2-amino-(9CI) is utilized as a key component in the synthesis of drugs. Its ability to participate in various chemical reactions makes it a valuable asset in the development of new medications.
Used in Metalloenzyme Research:
3-Pyridinethiol,2-amino-(9CI) is used as a ligand for metal ions in metalloenzyme research. Its interaction with metal ions allows scientists to study the structure, function, and mechanisms of metalloenzymes, contributing to a better understanding of these biologically important enzymes.
Used in Drug Development:
Due to its biological activity and potential as a ligand for metal ions, 3-Pyridinethiol,2-amino-(9CI) is employed in drug development. Its unique properties make it a promising candidate for the creation of new drugs targeting various diseases and conditions.

InChI:InChI=1/C5H6N2S/c6-5-4(8)2-1-3-7-5/h1-3,8H,(H2,6,7)

Upstream product

• 125209-79-2 bis(2-amino-3-pyridyl) disulfide 
• 551950-47-1 3-(tertbutylthio)pyridin-2-amine 

Downstream Products

• 125209-79-2 bis(2-amino-3-pyridyl) disulfide 

Relevant articles and documents

PROTEIN TYROSINE PHOSPHATASE INHIBITORS

Compounds of Formula la or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases in the view of their ability to inhibit SHP2. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

Comprehensive Analysis of Structure-Activity Relationships of α-Ketoheterocycles as sn-1-Diacylglycerol Lipase α Inhibitors

Diacylglycerol lipase α (DAGLα) is responsible for the formation of the endocannabinoid 2-arachidonoylglycerol (2-AG) in the central nervous system. DAGLα inhibitors are required to study the physiological role of 2-AG. Previously, we identified the α-ketoheterocycles as potent and highly selective DAGLα inhibitors. Here, we present the first comprehensive structure-activity relationship study of α-ketoheterocycles as DAGLα inhibitors. Our findings indicate that the active site of DAGLα is remarkably sensitive to the type of heterocyclic scaffold with oxazolo-4N-pyridines as the most active framework. We uncovered a fundamental substituent effect in which electron-withdrawing meta-oxazole substituents increased inhibitor potency. (C6-C9)-acyl chains with a distal phenyl group proved to be the most potent inhibitors. The integrated SAR data was consistent with the proposed binding pose in a DAGLα homology model. Altogether, our results may guide the design of future DAGLα inhibitors as leads for molecular therapies to treat neuroinflammation, obesity, and related metabolic disorders.

CARBACEPHEM β-LACTAM ANTIBIOTICS

Carbacephem -lactam antibiotics having structure (I) are disclosed, including stereoisomers, pharmaceutically acceptable salts, esters and prodrugs thereof, wherein Ar1, Ar2, R1 and R2 are as defined herein. The compounds are useful for the treatment of bacterial infections, in particular those caused by methicillin-resistant Staphylococcus spp.

CARBACEPHEM β-LACTAM ANTIBIOTICS

Carbacephem β-lactam antibiotics having the following chemical structures (I) and (II) are disclosed, including stereoisomers, pharmaceutically acceptable salts, esters and prodrugs thereof, wherein Ar2, R1, R2 and R3 are as defined herein. The compounds are useful for the treatment of bacterial infections, in particular those caused by methicillin-resistant Staphylococcus spp.